Filing summary
Filing identity: The supplied filing is KemPharm, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2022 (filed August 12, 2022), not a filing identified as Zevra Therapeutics, Inc. Verify the issuer before relying on this summary.
Business context and reporting period
KemPharm was a specialty pharmaceutical company developing CNS and rare-disease treatments using its LAT prodrug platform. Its approved product AZSTARYS was commercialized by Corium under a license agreement. Its pipeline included KP1077 for idiopathic hypersomnia and narcolepsy, KP879 for stimulant use disorder, and newly acquired arimoclomol for Niemann-Pick disease type C. Figures below are in U.S. dollars; financial statements are unaudited.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net revenue | $1.3 million | $12.0 million | $5.3 million | $24.1 million |
| Operating expenses | $26.1 million | $6.2 million | $31.9 million | $11.3 million |
| Operating income (loss) | ($24.8 million) | $5.8 million | ($26.6 million) | $12.8 million |
| Net income (loss) | ($24.0 million) | $6.2 million | ($25.9 million) | ($4.1 million) |
| Net loss per share attributable to common stockholders | ($0.70) | ($0.40) | ($0.75) | ($2.42) |
| Operating cash flow | Not separately stated for quarter | Not separately stated for quarter | ($7.7 million) | $14.0 million |
At June 30, 2022, cash and cash equivalents were $76.8 million; short- and long-term investments totaled $37.7 million, for combined cash, cash equivalents and investments of approximately $114.5 million. Current assets were $87.4 million and current liabilities $7.2 million. The company had $12.8 million outstanding on a $20 million revolving credit facility, with $20 million of certificates of deposit pledged as collateral. No convertible notes were outstanding. The filing does not present a single headline margin measure; reported results were heavily affected by the acquired in-process R&D charge.
Material changes versus prior comparable periods
- Q2 revenue declined $10.7 million year over year, primarily because 2021 included $10.0 million of KP415 license milestone revenue and more Corium consulting revenue. Q2 2022 revenue included $0.9 million from the arimoclomol Early Access Program (EAP).
- Six-month revenue decreased $18.8 million, mainly reflecting approximately $19.9 million less KP415 license revenue than in 2021.
- Q2 2022 included a one-time $17.7 million acquired in-process R&D expense from the arimoclomol asset acquisition. R&D and general and administrative expenses also increased year over year.
- Six-month operating cash flow moved from $14.0 million provided to $7.7 million used. The 2021 comparison included a $16.1 million noncash debt-extinguishment loss added back in the cash-flow reconciliation.
- Cash and cash equivalents fell by $35.6 million during the first half of 2022. Investing cash use was $36.9 million, including $14.1 million of net acquisition costs and $23.8 million of investment purchases.
Outlook, commentary, risks and unusual items
- Management said existing cash, cash equivalents and investments were expected to fund operations through and beyond 2025, based on its current forecast. The estimate excluded projected revenue, including royalties and milestone payments; management cautioned that funding sources and cash needs may differ from expectations.
- Management anticipated ongoing significant expenses and minimal or negative operating cash flow while advancing development programs and pursuing regulatory approvals. It identified possible funding from license payments, consulting, arimoclomol EAP sales, or additional financing; none is assured.
- Management planned to initiate a KP1077 Phase 2 IH trial as early as the second half of 2022, following FDA clearance of the submitted IND, and anticipated a narcolepsy trial thereafter. The filing listed arimoclomol NDA submission as early as Q1 2023. These are forward-looking plans, not guaranteed outcomes.
- The arimoclomol acquisition closed May 31, 2022. The company paid $12.8 million cash, assumed an estimated $5.2 million EAP reserve liability, and recorded $17.7 million of acquired IPR&D expense. The EAP liability, including additional clawback liability, was estimated at $5.7 million at quarter-end; the estimate depends on French pricing and repayment assumptions.
- The $20 million Ameris Bank facility matures no later than May 31, 2025, bears interest at SOFR plus 1.60% (subject to a 0% floor), and is secured by deposit accounts. Its certificates of deposit are pledged and cannot be redeemed while the facility remains active.
- Risks highlighted include clinical and regulatory uncertainty, dependence on partner-driven commercial revenues and milestones, acquisition integration and execution, possible future financing dilution or debt, and effects of COVID-19, inflation, interest rates and geopolitical developments. The company reported no material pending litigation and no material change to previously disclosed risk factors beyond the additions described.
Most important facts for investors to verify
- Confirm the issuer and filing: this document is for KemPharm, Inc., not Zevra Therapeutics, Inc.
- Check subsequent results for AZSTARYS royalties, licensing milestones, and arimoclomol EAP sales and clawback estimates.
- Assess the assumptions behind management’s cash runway through and beyond 2025, particularly the exclusion of projected revenue and the $20 million of pledged certificates of deposit.
- Track FDA clearance and clinical-trial timing for KP1077, and regulatory progress toward the arimoclomol NDA.
- Review acquisition integration, the assumed EAP reserve liability, and the ongoing expense and cash-flow impact of the expanded pipeline.
- Monitor potential dilution from equity awards and outstanding warrants, as well as the status of the share repurchase program; the company had repurchased approximately $7.5 million of shares by June 30, 2022.